quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:22·316d
PRRelease
Alnylam Pharmaceuticals Inc. logo
Instil Bio Inc. logo

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

ALNY· Alnylam Pharmaceuticals Inc.TIL· Instil Bio Inc.
Health Care
Original source

Companies

  • ALNY
    Alnylam Pharmaceuticals Inc.
    Health Care
  • TIL
    Instil Bio Inc.
    Health Care

Recent analyst ratings

  • Mar 16ALNYUpdateJefferies$330.00
  • Jan 28ALNYUpdateBarclays$527.00
  • Jan 7TILUpdateH.C. Wainwright-
  • Jan 7ALNYUpdateOppenheimer$500.00
  • Jan 6TILUpdateRobert W. Baird$7.00
  • Aug 4ALNYUpdateWolfe Research-

Related

  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • PR7d
    Alnylam to Webcast Conference Call Discussing First Quarter 2026 Financial Results
  • INSIDER16d
    SEC Form 4 filed by Mclaughlin Melissa
  • INSIDER16d
    SEC Form 3 filed by new insider Mclaughlin Melissa
  • SEC17d
    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.
  • SEC17d
    SEC Form DEF 14A filed by Alnylam Pharmaceuticals Inc.
  • SEC20d
    Instil Bio Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
  • PR24d
    New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022